FDA approved two anti-CD19 CAR-T cell products: Yescarta and Kymriah used to treat patients with recurrent and/or refractory NH [23], Kymriah was initially approved in the USA for relapsed or refractory pediatric or young adult B-cell precursor acute lymphoblastic leukemia in 2017, and subsequently approved for adults with relapsed or refractory diffuse large B-cell lymphoma in early 2018 [24]. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.